Skip to content Skip to footer
Subscribe Now
Awareness Campaign: Catherine Frenette from Gilead in Conversation with PharmaShots
VIEWPOINTS

Awareness Campaign: Catherine Frenette from Gilead in Conversation with PharmaShots

Shots:  At this year’s European Association for the Study of the Liver (EASL) Congress in Amsterdam, Gilead shared new data and 29 abstracts, including three oral presentations. But the data wasn’t the only thing that got people talking about Gilead’s commitment to transforming the lives of people living with liver conditions  EASL saw the launch…
August 18, 2025

Read more

GSK New
NEWS

GSK Reports the US FDA’s NDA Acceptance of Linerixibat for Primary Biliary Cholangitis (PBC) Patients with Cholestatic Pruritus

Shots: The US FDA has accepted NDA of linerixibat for the treatment of cholestatic pruritus in PBC pts (PDUFA: Mar 24, 2026) NDA is supported by P-III (GLISTEN) trial assessing linerixibat (n=119) vs PBO (n=119) to treat 238 PBC pts with cholestatic pruritus; pts could switch to linerixibat in Part B of the trial Trial…
June 2, 2025

Read more

GSK New
NEWS

GSK Reports the P-III (GLISTEN) Study Results of Linerixibat for Primary Biliary Cholangitis (PBC) Patients with Cholestatic Pruritus

Shots: GSK has reported P-III (GLISTEN) trial data assessing linerixibat (n=119) vs PBO (n=119) to treat PBC pts (N=238) with cholestatic pruritus; pts could switch to linerixibat in Part B of the trial Trial met its 1EP, showing significantly reduced itch per WI-NRS scale in PBC pts, as assessed by monthly itch score, over 24wks.…
May 8, 2025

Read more